PetLife Pharmaceuticals Inc

2. Escozine for Pets TM New frontier in pet oncological treatment; based on blue scorpion venom, which has been used for years to to treat humans with cancer in many countries Revolutionary new drug, with proven ability to reduce tumor size- no signs of toxicity or complications observed during clinical use. Can be easily administered, has healthy profit margins, market acceptance will be quick, translating to high sales growth

3. The Problem Pets are living longer than ever before, making them more susceptible to developing cancer Cancer is the # 1 disease related cause of death for dogs in the U.S. Cancer accounts for almost 50% of deaths in pets older than 10 years Average costs to treat lymphoma in pets is $2,000-most owners will rather watch their pets die than pursue treatment 1 in 4 dogs and 1 in 5 cats will develop cancer in their lifetime Dogs get cancer at about the same rate as humans

4. Current Solutions The most common treatment modalities used to combat cancer include: Surgical treatment, Chemotherapy, Radiation Therapy and Immunotherapy. PALLADIA is the first and only FDA-approved drug for canine cancer. While it is administered orally, it is still technically chemotherapy. Side effects may include low white blood cell counts, diarrhea, vomiting, lethargy, fatigue, and stomach ulceration. Low response rate, “roughly 40% of dog with mast cell tumors will actually respond to the drug, while the majority do not.” (US National Library of Medicine National Institutes of Health)

6. Market Opportunity Breakdown: Spending on Pets in 2015 ($ billions) • In 2015, $60.28 billion was spent on pets in the U.S.-26% on vet care services Food 23.05 Supplies/OTC Medicine 14.28 Vet Care 15.42 Live animal purchases 2.12 Pet Services: grooming & boarding 5.41

7. Market Opportunity Current treatment methods are quite expensive and not totally safe for pets Initial visit, including diagnosis, discussion of prognosis and a treatment plan $200+ Major surgery to remove a tumour deep in the body, or that requires reconstruction $1500+ Chemotherapy (depends on the size of the dog) ranges from $200 to $2,000 and up Radiation therapy ranges from $2,000 to $6,000 Pain medications $25 to $50 a month.

8. CASE REPORT Prohibitive treatment costs means some owners have no choice but to let their pets die rather than seeking further treatment I Amountspent: $3,000 Posted by : Irena in Vancouver. CA, Breed: Shepxgolden Treatment : Owner Took no action/did not seek further treatment Posted : March 3rd, 2011 08:03 PM Cancer Type : Intestinal “My beautiful 12 years boy started vomiting and lost 20 lb. Bl.test 2x, great, extray stomach , lungs great. Everything was great, but Sky was starved to death in front my eyes. 2 months nightmare, cry from pain, cannot eat, horrible. Ultrasound – mass tumor. Surgery, just open his belly told me cancer is in lymp.nodes, have one months to live if most. My boy suffered so much, so much , I let him go, when sleep on oper, table, hug him and let him go. I cant let him suffer more. Was very, just like that, on and off 2 months.”

9. Introducing a new generation of HP (high potency) veterinary cancer medications and nutraceuticals NEYMAR BLACK Entertainment Escozine for Pets™ Immunity Booster Escozine for Pets™ Escozine for Pets™ Supplements and Nutraceuiticals

10. Escozine for Pets™ • Escozine™ for Pets ™ is a an innovative polarized, potentiated bio-active peptide extracted from the Blue Scorpion (Rhopularus Princeps) • Induces apoptosis on a variety of cancer cells by a pattern of DNA fragmentation • It is based on the same-patented formula of “Escozine” used for the treatment of cancer in humans but is amplified through polarization technology

11. ESCOZINE FOR PETSTMinhibits blood vessel growth (angiogenesis) in solid tumors. Chlorotoxin blocks trans-membrane fluxes of chlorine and regulates the adjusting of cell growth, cell division and metastasis thereby inducing tumor cell death (apoptosis). The regulating of activity of the potassium (K+) 3-4 kDa, sodium (N+) 6-8 kDa and chloride (CL+) voltgate ionic channels of the tumor cells leads to growth arrest and causes cell death (apoptosis); additionally, calcium dependent potassium channels inhibit growth of other cancer cells. Innovation Therapeutics (2015). Review of Pre-clinical & Clinical data and Scorpion Venom studies to further support clinical research & development and registration of EscozineTM for Pet Life.

12. Escozine for Pets™ Escozine for Pets™ has a number of advantages over current treatment regimens • It can be used along with the traditional forms of cancer treatment • Sensitizes cancer cell resistance, thereby increasing the efficacy of other drugs used in treating the cancer in the animal. • Has selective binding preferences with malignant cells . • Easy administering orally • Cost effective

13. Escozine™ - A Breakthrough in Cancer Treatment and Prevention Documented clinical observations : • Reduction in pain • Enhancement of the recipient’s immune-system • Reduction of cancerous cell multiplication • Inhibition of new blood vessel formation from pre-existing cancerous cells. • Improvement in quality of sleep • Reduction of inflammation • Dramatic reduction in the painful side-effects of chemotherapy and radiation treatment • Improvement of appetite

14. Testimonials It has now been almost 1 year and 5 months since Bootsie's lung tumor diagnosis and 1 year and 3 months of being on Escozine. I can't thank the PetLife team and our vet, Dr Mitchell, for making this and introducing it to us. I never imagined she would still be with us today. If you saw and interacted with Bootsie, you wouldn't even know she had a tumor. She is an up beat 16 year old cat (if there is such a thing) who still loves sitting by the window sun bathing and watching the birds, playing and grooming her sisters (2 younger cats), and snuggling with my husband and me. When we started Bootsie on the Escozine, we were only hoping for it to help her lung tumor, however, we think it may be helping other health conditions she has. For the last 5 or so years now, Bootsie has had kidney disease as well. Just 2 months ago (Oct 2015) when our doctor did a routine blood panel check and urine check for her kidneys, her results look the best they've been in a few years! We are amazed at what this is doing for our baby's health. For a then 15 year old cat who was given only 3 months to live now being 16 years old and making it 1 year and 5 months past diagnosis is a true miracle for us. Thanks again, Escozine! anonymous anonymous

15. Testimonials My 9-year-old toy poodle, Ophelia, developed multiple breast lumps. She's been under the care of Dr. Joel Beth Mitchell of Aventura Animal Hospital and Resort. Dr. Mitchell had to perform several extensive surgeries in order to remove them all. Some biopsy results came back as low-grade carcinomas. We were devastated. Those were very dark times. Dr. Mitchell, whose opinion we hold in the highest regard, told us about Escozine. Some of her cancer patients who had had grim prognoses in the past, are alive and well, and they are taking Escozine. I was intrigued and encouraged, started reading a lot of literature on blue scorpion venom and decided to try it. I'm so glad I did. Ophelia has recovered remarkably well after very difficult surgeries. She's happy, full of energy and does not show any signs of sickness anymore, thank G-d. Escozine is very easy to administer. I only wish I could teach Ophelia to take it herself😊. Very grateful to Dr. Mitchell and Escozine team. Please continue your research and development. It benefits animals and people as well. Thank you! anonymous

16. Revenue Model Step 1. It is important that we first generate interest in Escozine for PetsTM. We will generate “buzz” through online articles, social media posts, videos, and during animal events Step 2. An animal specialist analyzes the needs of the animal and prescribes Escozine for Pets alone or in combination with other treament Step 3: Management of pet condition. The pet is monitored to ensure it is responding to treatment. Step 4: Encourage owners whose pets have been cured to spread word about Escozine anonymous

17. Revenue Growth to be Driven by New Customer Acquisitions • Expanding into new geographical markets. Each year, the company will open a new distribution center in a strategic geographical market i.e. India, Latin America and others • Ease of availability, cost effectiveness, easy administering, and aggressive brand building activities, will drive sales increases at a fast pace, year on year

18. Competition Description Competitor Company/Drug Conditionally approved by FDA in 2010, Kinavet-CA1®, is a tyrosine kinase inhibitor. It is used to treat mast cell tumors, a common form of cancer that affects dogs. Kinavet-CA1® works in three ways: by blocking the survival signal of the tumor cells, which may induce disappearance of the tumor, by preventing tumor growth and preventing the spread of tumor cells (metastasis). Paccal Vet®‑CA1 has been granted conditional approval by the FDA for the treatment of: non-resectable stage III, IV or V mammary carcinoma in dogs that have not received previous chemotherapy, or radiotherapy and resectable and non-resectable squamous cell carcinoma in dogs that have not received previous chemotherapy, or radiotherapy. The only drug fully approved by the FDA for the treatment of cancer in canines is Palladia. Palladia is a prescription-only therapy is used to treat grade II or III recurrent cutaneous mast cell tumors with or without regional lymph node involvement. It works by blocking the activity of key receptors important in the development of blood vessels that supply tumors, as well as receptors vital for tumor survival.

19. Competitive Advantage Esozine for Pets™ will succeed against competition in a number of areas: • Toxic cancer treatments for pets creates pent up demand for PetLife’s non-invasive products. • Patent Protection: PetLife has an exclusive license and rights to the patent on Polarized Scorpion Venom • Projected rapid sales growth and high gross margins: gives room to adjust pricing for competitiveness • Complementary treatment properties: Escozine for PetsTMcan be used as complementary treatment to chemotherapy drugs

20. Positioning We will position Escozine for Pets™ in the market as a non-invasive, cost effective ($249 cost of treatment per patient for each month) drug in the pet oncology market

21. Marketing and Growth Strategy Petlife’s primary marketing strategy is premised on building brand awareness, and rapid penetration of strategic geographical markets. Infomercials – Both online and offline to educate pet owners about cancer risk in Pets. Product bundling - market Escozine for Pets ™ and supplements as treatments that symbiotically work with one another and can effectively treat cancer in pets. Multi-local launches-Running online and offline launches for each new geographical market. This will help localize and establish PetLife’s brand and products, and help improve Google search rankings

22. Partnership is our winning strategy PetLife will sell Escozine for PetsTMto veterinarians using multiple respected veterinarian centers of influence to promote the product. Incentives will be provided to veterinarians to market the company’s products. Independent veterinarians will voluntarily help the company conduct clinical trials of its drugs.

23. Financial Projections Escozine for Pets™ line of nutraceuticals will launch in 2017, helping the business immediately start generating cash. High product margins and slow increase in operating costs against sales. High product margins, and fast revenue growth across all product categories (more than 100% sales growth in the first three years) will see the company in a healthy cash positition

24. Investment Proposal Petlife Pharma is seeking to raise $8.5 million through a private placement offering to fund the approval and launch of Escozine for Pets™. The initial part of our raise is $400,000. • $6.88 million is earmarked for Multi-Center Clinical Studies for Escozine for Pets™. These studies will include testing of safety and toxicity as well as determining appropriate doing parameters. It is estimated that these studies can be completed in 18-22 months • Once initial safety and toxicity studies are performed the Company may consider applying for Compassionate Use approval in certain animal cancers. This could occur in a few as 9 months.

25. Investment Proposal In return for $8.5 million, the company shall issue 17,000,000 shares to investors, which are equal to a 22.5% stake in the company after dilution.

26. Investment Proposal High Free Cash Flow generating potential

27. Key Milestones

28. Sources • DRESSLER, D. (2009). Palladia, First Dog Cancer Drug FDA Approved But Not Great. Retrieved May 29, 2016, from • http://www.dogcancerblog.com/blog/first-dog-cancer-drug-fda-approved-but-not-great/ • The Ins and Outs of Cancer in Pets. (2016). Retrieved May 29, 2016, from • http://www.vosrc.net/blog/the-ins-and-outs-of-cancer-in-pets/ • How Much Does Dog Cancer Treatment Cost? - CostHelper.com. (n.d.). Retrieved May 29, 2016, from • http://pets.costhelper.com/dog-cancer-treatment.html • Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. (2009, June/July). Retrieved May 29, 2016, from • http://www.ncbi.nlm.nih.gov/pubmed/19470739 • Pet Cancer Facts and Figures. (n.d.). Retrieved May 29, 2016, from • http://www.petinsurance.com/healthzone/pet-articles/pet-infographics/Pet-Cancer-Facts-and-Figures-Infographic.aspx • Pet Industry Market Size & Ownership Statistics. (n.d.). Retrieved May 29, 2016, from • http://www.americanpetproducts.org/press_industrytrends.asp • Rusk, A., Dr. (n.d.). Cancer is the leading cause of death in dogs and cats. Retrieved May 29, 2016, from • http://www.vetcontact.com/en/art.php?a=773